These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17205532)

  • 1. Detection of tumor-specific DNA in blood and bone marrow plasma from patients with prostate cancer.
    Schwarzenbach H; Chun FK; Lange I; Carpenter S; Gottberg M; Erbersdobler A; Friedrich MG; Huland H; Pantel K
    Int J Cancer; 2007 Apr; 120(7):1465-71. PubMed ID: 17205532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer.
    Schwarzenbach H; Müller V; Beeger C; Gottberg M; Stahmann N; Pantel K
    Breast Cancer Res; 2007; 9(5):R66. PubMed ID: 17915011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite analysis of allelic imbalance in tumour and blood from patients with prostate cancer.
    Schwarzenbach H; Chun FK; Müller I; Seidel C; Urban K; Erbersdobler A; Huland H; Pantel K; Friedrich MG
    BJU Int; 2008 Jul; 102(2):253-8. PubMed ID: 18336598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of Loss of Heterozygosity (LOH) Using Circulating Cell-free DNA (cfDNA) by Fluorescence-based Multiplex PCR for Identification of Patients With Prostate Cancer.
    Seyedolmohadessin SM; Akbari MT; Nourmohammadi Z; Basiri A; Pourmand G
    Appl Immunohistochem Mol Morphol; 2018; 26(10):749-759. PubMed ID: 28362710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of genetic alterations detected in circulating microsatellite DNA in blood plasma samples of patients with prostate cancer and benign prostatic hyperplasia.
    Müller I; Urban K; Pantel K; Schwarzenbach H
    Ann N Y Acad Sci; 2006 Sep; 1075():222-9. PubMed ID: 17108215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of tumor-specific genetic alterations in bone marrow from early-stage breast cancer patients.
    Taback B; Giuliano AE; Hansen NM; Singer FR; Shu S; Hoon DS
    Cancer Res; 2003 Apr; 63(8):1884-7. PubMed ID: 12702578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer.
    Schwarzenbach H; Pantel K; Kemper B; Beeger C; Otterbach F; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res; 2009; 11(5):R71. PubMed ID: 19772563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy.
    Kuhlmann JD; Schwarzenbach H; Otterbach F; Heubner M; Wimberger P; Worm KH; Kimmig R; Kasimir-Bauer S
    Genes Chromosomes Cancer; 2011 Aug; 50(8):598-605. PubMed ID: 21563231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.
    Kuhlmann JD; Schwarzenbach H; Wimberger P; Poetsch M; Kimmig R; Kasimir-Bauer S
    BMC Cancer; 2012 Jul; 12():325. PubMed ID: 22849543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity in serial plasma DNA samples during follow-up of women with breast cancer.
    Wang Q; Larson PS; Schlechter BL; Zahid N; Finnemore E; de las Morenas A; Blanchard RA; Rosenberg CL
    Int J Cancer; 2003 Oct; 106(6):923-9. PubMed ID: 12918071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microsatellite alterations plasma DNA of primary breast cancer patients.
    Shaw JA; Smith BM; Walsh T; Johnson S; Primrose L; Slade MJ; Walker RA; Coombes RC
    Clin Cancer Res; 2000 Mar; 6(3):1119-24. PubMed ID: 10741742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer.
    Chen X; Bonnefoi H; Diebold-Berger S; Lyautey J; Lederrey C; Faltin-Traub E; Stroun M; Anker P
    Clin Cancer Res; 1999 Sep; 5(9):2297-303. PubMed ID: 10499596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of loss of heterozygosity on circulating free DNA in peripheral blood of prostate cancer patients: potential and technical improvements.
    Müller I; Beeger C; Alix-Panabières C; Rebillard X; Pantel K; Schwarzenbach H
    Clin Chem; 2008 Apr; 54(4):688-96. PubMed ID: 18281424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence.
    Rawnaq T; Schwarzenbach H; Schurr PG; Freise K; Brandl S; Izbicki JR; Kaifi JT
    J Surg Res; 2011 Jul; 169(1):31-5. PubMed ID: 20417938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression.
    Schwarzenbach H; Eichelser C; Kropidlowski J; Janni W; Rack B; Pantel K
    Clin Cancer Res; 2012 Oct; 18(20):5719-30. PubMed ID: 23014523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detailed mapping and clinical significance of loss of heterozygosity on 9p13-23 in laryngeal squamous cell carcinoma by microsatellite analysis].
    Xu XF; Tang PZ; Cheng SJ
    Ai Zheng; 2003 May; 22(5):452-7. PubMed ID: 12753701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and characterization of circulating microsatellite-DNA in blood of patients with breast cancer.
    Schwarzenbach H; Müller V; Stahmann N; Pantel K
    Ann N Y Acad Sci; 2004 Jun; 1022():25-32. PubMed ID: 15251935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allelic loss at 16q23.2 is associated with good prognosis in high grade prostate cancer.
    Fromont G; Valeri A; Cher M; Pontes JE; Vallancien G; Validire P; Latil A; Cussenot O
    Prostate; 2005 Dec; 65(4):341-6. PubMed ID: 16015610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LOH analysis of free DNA in the plasma of patients with mucosal malignant melanoma in the head and neck.
    Takagi R; Nakamoto D; Mizoe JE; Tsujii H
    Int J Clin Oncol; 2007 Jun; 12(3):199-204. PubMed ID: 17566843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
    Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
    BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.